At Imbria, we are using our deep understanding of energy metabolism to develop novel therapies to substantially improve the lives of patients with life-altering diseases. Imbria is focused on developing new treatments that enhance or restore how cells produce energy. Where today’s standards of care often affect a cell’s environment, our product candidates are designed to help the cell intrinsically function better through more efficient energy metabolism.
We have developed a pipeline of novel product candidates centered on two key areas in energy metabolism: heart disease and inborn errors of metabolism. Our approach to drug development is based on targeting known mechanisms, validated biology and our expertise in both large population indications, such as cardiovascular disease, and in orphan disease indications, such as those arising from inborn errors of metabolism.